Imperial and Agilent renew partnership for flagship analytical science facility
Imperial and Agilent Technologies have announced the extension of their partnership to support advanced analytical science.
New partnership will use molecular glues to tackle ‘undruggable’ disease targets
Researchers at Imperial, the Francis Crick Institute and AstraZeneca will advance the discovery of new ‘molecular glues’ to treat a range of diseases.
Research shows how human cells are protected when the immune system switches on
Researchers show how a mechanism that human cells use to protect themselves against overzealous immune responses can be hijacked by invading bacteria.
UV-light activated probe finds new interactions in living cells
New research has discovered novel protein-protein interactions using a technique that does not require genetic manipulation of cells
Professor Ed Tate appointed to the GSK Chair in Chemical Biology
A prestigious Chair position will enable Imperial’s Professor Ed Tate to make further advances in chemical biology and drug discovery.
Wearable tech, AI and clinical teams join to change the face of trial monitoring
A multi-disciplinary team of researchers has developed a way to monitor the progression of movement disorders using motion capture technology and AI.
Feature
Innovation and entrepreneurship at Imperial: A year in review
Imperial’s enterprising ecosystem has flourished in 2022.
CRISPR-based oligo recombineering in drug discovery
Congratulations to Henry Benns for his first-author publication in Nature Microbiology
Observing the early universe and supporting net-zero: News from the College
Here’s a batch of fresh news and announcements from across Imperial.
Epigenetic treatment in mice improves spinal cord regeneration after injury
New Imperial-led research shows that weekly epigenetic treatment in mice can support spinal cord regeneration after severe injury.
